文献速递慢性肾脏病肾血管病与高血压

美国肾功能受损人群中ACEI/ARB使用趋势

Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States.
PubMed 文献 · J Am Soc Nephrol · 2019-06-05

该研究基于1999-2014年美国NHANES中38,885名eGFR<60或UACR≥30的成人,分析ACEI/ARB使用趋势。在7,085名CKD患者中,总体使用率为34.9%,各时期使用率显著上升(1999-2002年25.5%至2011-2014年40.1%),但2003年后趋于平台。使用与非西班牙裔白人、黑人及多个临床因素独立相关。

要点

  • CKD患者ACEI/ARB使用率从1999-2002年的25.5%升至2011-2014年的40.1%,但2003年后趋于平台。
  • 非西班牙裔黑人和白人使用率较高(38.2%和36.1%),西班牙裔和其他种族较低(26.7%和29.3%)。
  • 调整后,2003-2006、2007-2010、2011-2014相比1999-2002的aOR分别为1.41、1.84、2.02。

核心结论

  • 美国CKD成人ACEI/ARB使用率在2000年代初上升,但随后十年趋于平台。

研究设计与样本

  • 研究分析了1999至2014年NHANES中38,885名eGFR<60 ml/min per 1.73 m2或UACR≥30 mg/g的成人。
  • 其中7,085名参与者符合CKD定义,分析ACEI/ARB使用趋势及相关因素。

主要发现

  • CKD患者中ACEI/ARB总体使用率为34.9%。
  • 四个时期使用率分别为25.5%(1999-2002)、33.3%(2003-2006)、39.0%(2007-2010)、40.1%(2011-2014)。
  • 非西班牙裔白人、黑人、西班牙裔和其他种族使用率分别为36.1%、38.2%、26.7%、29.3%。
  • 调整年龄、性别、种族后,2003-2006、2007-2010、2011-2014相比1999-2002的aOR分别为1.41(95%CI 1.14-1.74)、1.84(95%CI 1.48-2.28)、2.02(95%CI 1.61-2.53)。
  • 非西班牙裔黑人相比非西班牙裔白人的aOR为1.40(95%CI 1.19-1.66)。

临床怎么用

  • 临床中应关注CKD患者ACEI/ARB的使用,尤其西班牙裔和其他种族使用率较低。
  • 需探究使用率平台的原因及障碍,以优化循证治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although hypertension is common in CKD and evidence-based treatment of hypertension has changed considerably, contemporary and nationally representative information about use of angiotensin-converting enzyme (ACEs) inhibitors or angiotensin II receptor blockers (ARBs) in CKD is lacking. METHODS: We examined ACE/ARB trends from 1999 to 2014 among 38,885 adult National Health and Nutrition Examination Survey participants with creatinine-based eGFR<60 ml/min per 1.73 m2 or urinary albumin-to-creatinine ratio ≥30 mg/g. RESULTS: Of 7085 participants with CKD, 34.9% used an ACE/ARB. Across four eras studied, rates of use rose significantly (rates were 25.5% in 1999-2002, 33.3% in 2003-2006, 39.0% in 2007-2010, and 40.1% in 2011-2014) but appeared to plateau after 2003. Among those with CKD, use was significantly greater among non-Hispanic white and black individuals (36.1% and 38.2%, respectively) and lower among Hispanic individuals (26.7%) and other races/ethnicities (29.3%). In age-, sex-, and race/ethnicity-adjusted models, ACE/ARB use was significantly associated with era (adjusted odds ratios [aOR], 1.41; 95% confidence interval [95% CI], 1.14 to 1.74 for 2003-2006, 1.84; 95% CI, 1.48 to 2.28 for 2007-2010, and 2.02; 95% CI, 1.61 to 2.53 for 2011-2014 versus 1999-2002); it also was significantly associated with non-Hispanic black versus non-Hispanic white race/ethnicity (aOR, 1.40; 95% CI, 1.19 to 1.66). Other multivariate associations included older age, men, elevated BMI, diabetes mellitus, treated hypertension, cardiac failure, myocardial infarction, health insurance, and receiving medical care within the prior year. CONCLUSIONS: Rates of ACE/ARB use increased in the early 2000s among United States adults with CKD, but for unclear reasons, use appeared to plateau in the ensuing decade. Research examining barriers to care and other factors is needed.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Murphy DP, Drawz PE, Foley RN, et al. Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States. J Am Soc Nephrol. 2019. PMID: 31167823. doi:10.1681/ASN.2018100971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。